{
    "organizations": [],
    "uuid": "78991484d8420257bec335cff35c8f05534b26e2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-helsinn-group-and-mei-pharmas-prac/brief-helsinn-group-and-mei-pharmas-pracinostat-receives-orphan-drug-designation-from-european-medicines-agency-idUSFWN1P6062",
    "ord_in_thread": 0,
    "title": "BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 11, 2018 / 8:12 AM / Updated an hour ago BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency Reuters Staff 1 Min Read \nJan 11 (Reuters) - Mei Pharma Inc: \n* HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:",
    "published": "2018-01-11T10:11:00.000+02:00",
    "crawled": "2018-01-11T10:30:22.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "updated",
        "hour",
        "ago",
        "group",
        "mei",
        "pharma",
        "pracinostat",
        "receives",
        "orphan",
        "drug",
        "designation",
        "european",
        "medicine",
        "agency",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "mei",
        "pharma",
        "inc",
        "helsinn",
        "group",
        "mei",
        "pharma",
        "announce",
        "pracinostat",
        "received",
        "orphan",
        "drug",
        "designation",
        "european",
        "medicine",
        "agency",
        "treatment",
        "acute",
        "myeloid",
        "leukemia",
        "aml",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}